Intravenous Immunoglobulin (IVIG) in Treating Non-ventilated COVID-19 Patients with Moderate to Severe Hypoxia is Pharmacoeconomically Favorable When Appropriately Targeted

Matthew Poremba, Matthew Dehner, Alexandra Perreiter, Ashley Semma, Kimberly Mills, George Sakoulas
doi: https://doi.org/10.1101/2021.09.26.21264152

Article usage

Article usage: September 2021 to January 2025

AbstractFullPdf
Sep 2021547689
Oct 20212632468
Nov 20211432143
Dec 2021893036
Jan 202257317
Feb 202258229
Mar 202259147
Apr 202254810
May 202265917
Jun 202247168
Jul 20225289
Aug 202240138
Sep 20223679
Oct 20223857
Nov 20222795
Dec 20221575
Jan 202328510
Feb 20231475
Mar 20231371
Apr 20232353
May 202312412
Jun 2023672
Jul 20231264
Aug 202323148
Sep 20231153
Oct 2023902
Nov 20231995
Dec 20231012
Jan 2024823
Feb 20241082
Mar 20241248
Apr 20241124
May 2024912
Jun 20241132
Jul 2024745
Aug 20241015
Sep 20241667
Oct 20241724
Nov 20241614
Dec 2024728
Jan 2025751
Back to top
Posted September 27, 2021.
Download PDF
Data/Code
Email
Intravenous Immunoglobulin (IVIG) in Treating Non-ventilated COVID-19 Patients with Moderate to Severe Hypoxia is Pharmacoeconomically Favorable When Appropriately Targeted
Matthew Poremba, Matthew Dehner, Alexandra Perreiter, Ashley Semma, Kimberly Mills, George Sakoulas
medRxiv 2021.09.26.21264152; doi: https://doi.org/10.1101/2021.09.26.21264152
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area